Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal
choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.